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The initiating factor(s) which triggers compensatory renal
growth (CRG) or the nature of regulator(s) activated following
the loss of kidney mass is still unknown. The existence of a
negative feedback mechanism [1—3] and of stimulating factor(s)
present in normal urine [4, 5] and plasma of unilaterally
nephrectomized mammals 16—101 have been suggested. The
involvement of the endocrine system, cyclic AMP, and cyclic
GMP has also been considered [11—131.
A possible link between cell proliferation and adenosine
(ADO) has been suggested [14—19]. Under normal conditions,
ADO levels are barely detectable in most cells due to the
combined action of ADase (adenosine aminohydrolase EC
3.5.4.4) which converts ADO to inosine in the metabolism of
purine nucleotides and adenosine kinase (EC 2.7.1.20), which
catalyzes the rephosphorylation of ADO into AMP. High
concentrations of exogenous ADO are toxic to cultures of
human lymphoblasts, fibroblasts [14—18] and leukemia cells
[19]. ADO apparently inhibits growth in vitro by reducing
pyrimidine nucleotides essential in RNA or DNA biosynthesis
[14, 20]. Since a series of biochemical alterations which preceed
DNA synthesis and cell division takes place in the contralateral
kidney following unilateral nephrectomy, we have attempted to
determine if ADase and ADO play some role in CRG. We find
that ADO appears to have a biphasic effect. It inhibits thymi-
dine incorporation into renal DNA but only at high concentra-
tions in vitro; total inhibition of renal ADase in vivo, with the
consequent elevation of intracellular ADO and far from arrest-
ing CRG, stimulates growth.
Methods
Materials. Adenosine and enzymes needed in the determina-
tion of ADase, ADO, ATP, ADP, and AMP were purchased
from Boehringer Ingeiheim Ltd., Ridgefield, Connecticut; thy-
midine [methyl-3H] at a specific activity of 6.7 Ci/mmole was
purchased from New England Nuclear Corporation, Boston,
Massachusetts. Hank's medium (Grand Island Biological Com-
pany, Grand Island, New York) BSS lox, without sodium
bicarbonate and without phenol red was diluted to a normal
concentration with double distilled water, and sterilized again
before use. Coformycin was a gift from Drs. J. Douros and M.
Suffness of the National Cancer Institute, Bethesda, Maryland.
Received for publication October II, 1982
© 1983 by the International Society of Nephrology
Reagent-grade chemicals were used throughout the
experiments.
Nephrectomy. Male Sprague-Dawley rats (150 to 160 g; 40 to
45 days old) were used. Right nephrectomy was performed
between 9 and 10 A.M. under a light ether anesthesia.
In vivo inhibition of renal ADase by coformycin (CF). The
magnitude of the reduction of ADase activity and its duration
were studied with different dosages of CF:
Low dosage (0.1 mg CF/kg body wt/24 hr). A solution of CF
(0.1 mg/kg) diluted in 0.5 ml NaCI 0.9% was injected intraperito-
neally into 16 rats around 9 A.M., and nephrectomy was
performed 40 mm afterwards. At the same time each following
day, a group of four animals was sacrificed while the remaining
animals received another dose of CF. The experiment ended on
day 4.
High dosage (0.2 mg/kg body wt/12 hr). A solution of CF (0.2
mg/kg) diluted in 0.5 ml NaCI 0.9% was injected into 16 rats
around 9 P.M. on a given day. A second injection was adminis-
tered 12 hr later (9 A.M.), and unilateral nephrectomy was
performed 40 mm afterwards. The animals received CF injec-
tions every 12 hr until 12 hr prior to sacrifice time. A group of
four animals was sacrificed 24, 48, 72, and 96 hr following the
nephrectomy.
ADase and ADO levels were determined in both the removed
and the regenerated kidneys. The tissue was homogenized in
0.1 M phosphate buffer, pH 7.0; the XIS 000g supernatant was
saved for assays. ADase activity was determined by the method
of Hopkinson et al modified by Trotta and Balis [21]. ADO was
determined by its conversion to inosine by ADase [22, 23]. The
decrease in its absorbance at 265 nm was recorded
spectrophotometrically.
Effect of coformycin on CRG. In vivo studies. Since only 12-
hr injections of high dosage (0.2 mg/kg) appear to bring total
inhibition of ADase for a long duration, the in vivo effects of CF
on CRG were studied at this dosage; the injections and nephrec-
tomies were carried out according to the schedule described
earlier.
To dissociate the effect of starvation brought about by the CF
treatment, rats were submitted to three different food regimes
after they were unilaterally nephrectomized. A group of 16
control and 16 experimental animals was given free access to rat
chow (Ralston Purina, St. Louis, Missouri) and water. A
second group of rats (12 control and 12 experimental) was given
access to water only. A third group of 6 control and 6 experi-
mental rats was fed orally four times daily with powdered milk
(SMA) dissolved in water; the amount given was equivalent to a
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total of 45 calories/l0O g body wt per day. They also had free
access to water. Three or four animals in each category were
sacrificed at various times postnephrectomy (24, 48, 72, and 96
hr). The dry or wet weight and protein content of the remaining
kidney was compared with those of the removed kidney taken
as control. Unilaterally nephrectomized control rats received
0.9% NaCl in lieu of CF.
Effect of coformycin in CRG. In vitro studies. The incorpo-
ration of thymidine-3H into DNA was studied with renal
cortical slices obtained from rats having undergone a right
nephrectomy 48 hr previously; this experiment was based on a
previous study by Martel-Pelletier and Bergeron [3] which
indicated that maximum synthesis of DNA was reached in CRG
after 2 days. Cortical slices (300 to 400 i) were cut with a
Stadie-Riggs microtome. The operation temperature was main-
tained at 4°C. Each slice was divided into a control hail and an
experimental half. Each control or experimental flask contained
three to four half-slices. Experimental slices were incubated at
37°C for 10 mm in Hank's solution containing various concen-
trations of CF (0.5 to 10.0 sg/ml) in a total of 5 ml of medium.
Thymidine-3H (4 pCilml) was added and incubated for another
30 mm. The control slices went through the same incubation
conditions, but the medium did not contain CF. The procedure
was stopped by placing the flasks on crushed ice. The slices
were washed three times in 5% TCA and 95% alcohol, and
DNA was extracted in 5% TCA (100°C for 10 mm). The specific
activity of DNA was expressed in cpm per 1000 O.D. units
read after a colorimetric reaction with diphenylamine.
Two other parallel experiments were performed: in one, renal
slices were exposed to CF (10 g/ml) and various concentra-
tions of ADO (0.05 to 1 mM/ml); in another, they were exposed
to ADO (0.25 to 2 mM/ml) without the presence of CF.
Thymidine-3H (4 pCiIml) was added after a 10-mm pre-incuba-
tion. The manipulation was carried out in the same manner as
above.
Effect of CF on the levels of renal adenine nucleotides and
cyclic nucleotides. The levels of ATP, ADP, AMP, and cAMP
were examined under the following circumstances:
• Normal rats
• Unilaterally nephrectomized rats
• Normal rats receiving high dosage of CF
• Unilaterally nephrectomized rats receiving high dosage of
CF.
The CF injections were carried out according to the schedule
described earlier, however, an extra dose was given 40 mm
prior to sacrifice. The animals were anesthesized with an
intraperitoneal injection of Somnotol (MTC Pharmaceuticals,
Hamilton, Canada; 0.09 ml/100 g body wt) 24 hr following the
nephrectomy or 24 hr following the second injection (9 A.M.) of
CF. Kidneys were removed with minimum handling and were
snap-frozen and crushed with flat-nose pliers precooled in
liquid nitrogen. The frozen tissues were plunged into liquid
nitrogen and subsequently weighed and extracted in 10% per-
chloric acid solution according to standard procedures.
ATP, ADP, and AMP were determined by enzymatic meth-
od. cAMP was estimated with a kit prepared by Amersham
Corporation, Arlington Heights, Illinois.
Results
In vivo effect of CF on renal ADase and ADO. Our data
shows that 40 mm following the first intraperitoneal injection of
0.1 mg CF/kg body weight total inhibition of ADase occurred in
the kidneys in 10 out of 16 animals. The ADO concentration
was found to be 1.34 smo1es 0.l9/g tissue (N = 10). In the
other six rats, ADase activity was reduced and ADO was not
detectable. The ADase examined in the remaining kidney
recovered 65% of its initial activity 24 hr following a single
injection, but the degree of recovery was reduced with continu-
ing treatment at 24-hr intervals. Only 26 to 30% of the initial
ADase activity was found on days 3 and 4.
When the dose was increased to 0.2 mglkg!l2 hr, the renal
ADase activity measured 40 mm after the second injection was
found to be completely inhibited in 22 out of 27 animals. The
ADO concentration was 0.95 jsmole 0.l6/g tissue (N = 22).
This value is lower than the value of 1.34 jimoles presented
earlier when ADO concentration was measured almost immedi-
ately upon the inhibition induced by the first CF injection.
Some ADO thus appears to be either metabolized via alterna-
tive pathways different from inosine or transported out of the
organ. With repeated CF injections at 12-hr intervals, only
traces of renal ADase were found in the remaining kidney when
it was examined 12 hr following a final injection. Although again
no ADO was detected, the level of ADO measured in an extra
group of rats with an extra dose of CF given 40 mm prior to
sacrifice — the aim of which was to eliminate those newly
occurred traces of ADase — was again around 0.95 mole as
indicated earlier. Whenever total inhibition of ADase was
maintained, ADO remained at the same level throughout. The
in vivo effect of CF on CRG, therefore, was studied at the high
dosage.
In vivo effect of coformycin on CRG. Unilateral nephrectomy
induced CRG in the remaining kidney of normal rats fed a
regular diet. The RNA, DNA, and protein content as well as the
renal mass also increased [24, 25] (Fig. 1). CF-treated animals
were listless and had no appetite. Their food intake was
minimal: They took only 10 to 15% of the amount of food
consumed by the controls. As seen in Figure 2A, B, and C, their
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Fig. 1. Effect of right unilateral nephrectomy on the principal parame-
ters of normal rats fed ad libitum. Each point is the mean of four
animals.
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Fig. 3. Changes in body weight (A) and kidney
dry weight (B) of uninephrectomized fasting
rats. An identical loss in body weight was
recorded in both control and CF-treated rats.
The mass of the remaining kidney of control
rats also dropped, but that of the CF-treated
rats showed a gain within the first 72 hr post-
nephrectomy. Each point is the mean SEM (N
= 3).
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body weight shows a dramatic drop which is almost at the same
level as that observed in fasting rats (Fig. 3A); however, CRG,
judged from the kidney wet weight and protein content, still
took place, although to a lesser extent than in well-fed control
rats. Due to the correlation between kidney weight, protein,
RNA, and DNA content seen in Figures 1 and 2B and C, dry
kidney weight was subsequently used as a parameter in the
assessment of CRG. Since starvation is a well known factor
which prevents CRG from occurring [26, 271, we compared the
normal and CF-treated fasting rats. The same degree of body
weight loss was seen in both groups (Fig. 3A). However, when
the dry weights of the regenerating kidneys were determined,
the CF-treated rats showed a different response; their kidney
dry weights actually increased within the first 72 hr, despite
starvation (Fig. 3B).
When the rats were given an isocaloric amount of food, the
CF-treated rats also rated better than their control counter-
parts. An increment of 23 and 31% (N = 3) over the control
kidney was noted at 72 and 96 hr postnephrectomy, respective-
ly, in CF-treated rats, as compared to an increment of 16 and
20% (N = 3) in the control rats. All animals in both groups
regained their original body weight.
In vitro incorporation of thymidine-3H into DNA of renal
cortex. The presence of CF in the incubating medium does not
exert any inhibitory effect on the incorporation of thymidine-3H
into the DNA of the regenerating renal cortex slices; in fact, one
observes a slightly higher incorporation (Table 1), which rules
out a cytotoxic effect of CF. When one considers the short
duration of the in vitro experiment, there is a possibility that
this slight acceleration could be more significant in vivo. This
could explain the higher rate of CRG observed in CF-treated
rats as noted earlier.
When ADO was added to the medium, the situation changed
dramatically as a marked inhibition was noted: 46% with 0.5
m ADO/mi and 68% with 1.0 m ADO/mi (Table 2).
To separate the potentializing effect of CF, the influence of
external ADO alone was studied. An inhibition was observed,
but many times the concentraton of ADO was needed to obtain
the same degree of inhibition (Table 3).
Effect of CF on the levels of adenine nucleotides and cyclic
nucleotides. The values of ATP (2.09 0.21 emoles/g tissue; N
9), ADP (1.67 0.15 moles/g tissue; N = 9), AMP (0.077
0.025 imoles/g tissue; N = 3), and cAMP (696 38 pmoles/g
tissue; N = 9) found in normal rat kidneys were not altered by
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Fig. 2. Changes in body weight (A), kidney wet weight (B), and kidney protein (C) content of uninephrectomized rats fed ad libitum. The CF-treated
rats, because of their diminished food intake brought about by CF, show a considerable loss in body weight, but CR0 was not inhibited. Each point
is the mean SEM (N = 4).
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Table 1. In vitro effect of coformycin on the incorporation of
thymidine-3H into regenerating renal cortex slicesa
Coformycin
gIml
DNA specific activity
cpmI100OD.O.,® %
0 150.2 12.2
0.5 157.8 14.6 +5.0 (NS)
0 127.7 12.6
1.0 128.6 9.3 (NS)
0 153.8 10.0
4.0 164.5 8.5 +6.9 (NS)
0 169.2 7.4
10.0 176.4 7.9 +4.2 (NS)
a Values are the mean SEM (N = 4); NS, not significant.
Table 2. In vitro effect of coformycin (10 g/m1) and external ADO on
the incorporation of thymidine-3H into regenerating renal cortex
slicesa
Adenosine
mM/mi
DNA specific activity
cpm/1000 D.O. % Inhibition
0 155.2 3.5 NS
0.05 151.8 8.2
0 178.3 13.1 46.1
0.5 96.0 5.0 (P < 0.01)
0 136.6 15.1 68.4
1.0 43.1 6.5 (P <0.005)
a Values are the mean SEM (N = 4).
CF treatment or unilateral nephrectomy under our experimental
conditions just described.
Discussion
ADO is produced, released, absorbed, and metabolized by
most animal tissues. As shown in Figure 4, the two major
metabolic pathways of ADO are the conversion to AMP by
adenosine kinase and the transformation to inosine by ADase.
A delicate balance between the two enzymes seems to
regulate ADO concentrations. Under normal conditions, ADO
is maintained at a very low level ranging from 1 to 30 nmoles per
g of wet weight of tissue, and from 0.03 to 2.6 m in body fluids
[28]. In general, ADO tends to remain at the cell site of
production rather than escape into the general circulation, but it
does not accumulate in the cell unless an ADase inhibitor is
present [29].
ADase is distributed widely in all tissues of the body. It is
bound tightly to CF upon the distribution of the latter into
tissues; the recovery of the enzyme activity is related to the
quantity of drug administered, its clearance into urine, and the
ability of the tissue to generate new enzyme activity [22].
Renal ADase in all normal adult rats was found to be
approximately 150 mU/mg protein as reported previously [23].
Its stability is remarkable: Identical values were found at
different times (2 to 96 hr) after unilateral nephrectomy. Renal
ADO is not detectable when ADase is not completely inhibited
which is why we carried out our studies with a high dosage of
CF. According to Chas sin et al [22], the injection of 2'-
deoxycoformycin produces a reduction of ADase activity to
Table 3. In vitro effect of external ADO in the absence of CF on the
incorporation of thymidine-3H into regenerating renal cortex slices
Adenosine
mM/mi
DNA specific activity
cpmIl000 D.O. % Inhibition
0 120.3 9Øa 5.4
0.25 113.8 8.2 (P = 0.13)
0 139.4 7.Oa 18.5
0.5 113.6±7.7 (P<0.005)
0 134.2 8.2a 31.8
1.0 91.4±6.2 (P<0.005)
0 l3lb
2.0 78 40.4
a Values are the mean SEM (N = 4).bN= 1.
less than 10% in many rat tissues (kidney, liver, heart, muscle,
and so forth) even at the low dosage of 0.1 mg/kg, but a
substantial degree of recovery seems to take place within 8 to 12
hr in most tissues, with the exception of erythrocyte ADase
which remains very low.
A wide range of physiological and a number of biochemical
effects of ADO have been reported. The addition of exogenous
ADO is associated with the inhibitions of cell growth, immune
response, coronary vasodilation, delayed neurotransmission,
lypolysis, and the inhibition or stimulation of hormone secre-
tion and so forth. Some of these were shown to be related to the
biochemical effects which include activation of the adenylate
cyclase systems, inhibition of pyrimidine synthesis, and alter-
ation of phosphoribosyl pyrophosphate metabolism.
The growth inhibition effect of ADO has been demonstrated
in cultures of human lymphoblasts and fibroblasts [14—18].
Impairment of thymidine incorporation into DNA was shown to
occur in mitogen-induced lymphocytes in the presence of ADO,
but, as shown in this study this occurs only when a millimolar
concentration was reached. The potentialization of these phe-
nomena by different ADase inhibitors, such as EHNA (erythro-
9(2-hydroxy3-nonyl) adenosine hydrochloride) or CF in combi-
nation with ADO was also found in previous in vitro studies [15,
16, 18, 19]. All indications point to the toxic role of high
concentrations of ADO, most likely due to the inhibition of
pyrimidine synthesis brought about by changes in adenine
nucleotide levels [14, 20]. This could explain why there is
increased ADase activity in kidney-developing cells [23] and
adult intestinal villus cells which carry out exogenous ADO
absorption [22].
The concentration of ADO appears to be an important factor
in the outcome of its biological or biochemical effect. The
biphasic effect of ADO on several adenylate cyclase systems
has been well demonstrated: activation occurring at a low
concentration through one receptor site and inhibition at a
higher concentration through another receptor site [30, 31].
While the toxic effect of high ADO concentrations is well
documented in cell cultures, much less has been reported on its
stimulatory effect. Carson and Seegmiller [15] also observed a
dual action of ADO on thymidine incorporation into human
lymphocytes, analogous to the one described here in kidney
cells.
Since the levels of purine nucleotides and the adenylate
cyclase activity were not modified in the presence of an
intracellular concentration of 0.95 M of ADO, this seems to
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Fig. 4. Metabolism of ADO (I) adenosine phos-
phorylase; (2) adenosine kinase; (3) 5'-nuc/eo-
tidase and nonspecficphosphatase; (4) ADase.
indicate that the ADO effect is not due to its direct transforma-
tion into purine nucleotides or cAMP, nor to its modulating
effect on their levels. ADO could thus play the role of a local
messenger, as suggested by Arch and Newsholme [281, exerting
a direct effect on the cytoplasmic components which are active
in stimulating DNA synthesis [32—341. This action could be
similar to the one exerted by diadenosine tetraphosphate in the
initiation of DNA replication [35, 361.
Our studies suggest that a low intracellular concentration of
ADO can enhance CRG and suppress the CRG inhibition
induced by starvation, but they do not demonstrate a key role
for ADO in the initiation of CRG: Renal ADase activity was not
modified nor was the intracellular ADO concentration in-
creased following mononephrectomy [231. However, this report
brings indirect evidence in favor of a negative feedback mecha-
nism essential for CRG to occur.
Summary. The role of ADO and ADase in CRG was studied
in unilaterally nephrectomized rats by using a specific ADase
inhibitor, CF. ADO appears to have a biphasic effect. In vitro,
ADO can inhibit the incorporation of thymidine-3H into DNA of
regenerating renal cortex slices but only at high concentrations:
Inhibition was 19% at 0.5 m and 32% at 1.0 m ADO/ml of
incubation medium. The same concentrations of ADO com-
bined with CF (10 ig!ml) yielded higher inhibitory effects: 46%
at 0.5 mM and 68% at 1.0 mst. In contrast, when regenerating
renal cortical slices were incubated with CF alone without
external ADO, thymidine-3H incorporation into DNA was
higher in these than in controls. When a complete inhibition of
ADase was achieved in vivo by injecting CF into rats, renal
ADO increased from minimal amounts to 0.95 j.mole/g kidney
0.16 (N = 22). CRG took place in coformycin-treated rats
even when rats were fasting. The levels of ATP, ADP, AMP,
and cAMP were not modified under the above conditions. We
postulate that enhanced CRG after CF treatment in unilaterally
mononephrectomized rats could be due to the intracellular
action of ADO acting as an alternate messenger of cell
proliferation.
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